Effectiveness of a clinical pathway with methadone treatment protocol for treatment of neonatal abstinence syndrome following in utero drug exposure to substances of abuse

Pediatric Critical Care Medicine

Volumn 15, Issue 2, 2014, Pages 162-169

  Bhatt Mehta, Varsha ^a   Ng, Chee M ^b   Schumacher, Robert E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Abstinence; Clinical pathway; Lipsitz; Methadone; Neonatal; Substance abuse; Treatment

Indexed keywords

ANALGESICS, OPIOID; CLINICAL PROTOCOLS; FEMALE; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; LENGTH OF STAY; MALE; METHADONE; NEONATAL ABSTINENCE SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84894041351     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3182a12611     Document Type: Article

References (14)

1. Substance Abuse and Mental Health Services Administration (SAMHSA): Results From the 2010 National Survey on Drug Use and Health: National Findings. Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD, SAMHSA, 2011
2. Osborn DA, Jeffery HE, Cole MJ: Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010; 10:CD002059
3. Patrick SW, Schumacher RE, Benneyworth BD, et al: Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012; 307:1934-1940
4. Hudak ML, Tan RC; COMMITTEE ON DRUGS; COMMITTEE ON FETUS AND NEWBORN; American Academy of Pediatrics: Neonatal drug withdrawal. Pediatrics 2012; 129:e540-e560
5. Jones HE, Kaltenbach K, Heil SH, et al: Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320-2331
6. Jones HE, Johnson RE, Jasinski DR, et al: Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: Effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79:1-10
7. Jones HE, Heil SH, Baewert A, et al: Buprenorphine treatment of opioid-dependent pregnant women: A comprehensive review. Addiction 2012; 107(Suppl 1):5-27
8. Lainwala S, Brown ER, Weinschenk NP, et al: A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv Neonatal Care 2005; 5:265-272
9. Isemann B, Meinzen-Derr J, Akinbi H: Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. J Perinatol 2011; 31:25-29
10. Lipsitz PJ: A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin Pediatr (Phila) 1975; 14:592-594
11. Finnegan LP, Kron RE, Connaughton JF, et al: Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol Biopharm 1975; 12:19-32
12. Olkkola KT, Hamunen K, Maunuksela EL: Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clin Pharmacokinet 1995; 28:385-404
13. Gerber JG, Rhodes RJ, Gal J: Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004; 16:36-44
14. Geraghty B, Graham EA, Logan B, et al: Methadone levels in breast milk. J Hum Lact 1997; 13:227-230